Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q01814
UPID:
AT2B2_HUMAN
Alternative names:
Plasma membrane calcium ATPase isoform 2; Plasma membrane calcium pump isoform 2
Alternative UPACC:
Q01814; O00766; Q12994; Q16818
Background:
Plasma membrane calcium-transporting ATPase 2, also known as Plasma membrane calcium ATPase isoform 2, plays a pivotal role in maintaining basal intracellular Ca(2+) levels in specialized cells. It is crucial for the functioning of cerebellar circuits, vestibular and cochlear systems, facilitating fast neuronal Ca(2+) dynamics, and is essential in hearing and balance. This protein mediates presynaptic Ca(2+) efflux and contributes to motor learning by controlling Ca(2+) clearance rates.
Therapeutic significance:
The protein's involvement in Deafness, autosomal dominant, 82, a form of sensorineural hearing loss, underscores its therapeutic significance. Understanding the role of Plasma membrane calcium-transporting ATPase 2 could open doors to potential therapeutic strategies for hearing loss and balance disorders.